The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): Personal experience and literature review

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Magnotti, Flora ^a   Vitale, Antonio ^a   Rigante, Donato ^b   Lucherini, Orso Maria ^a   Cimaz, Rolando ^c   Muscari, Isabella ^a   de Faria, Atila Granados Afonso ^d   Frediani, Frediani ^a   Galeazzi, Mauro ^a   Cantarini, Luca ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amyloidosis; Autoinflammatory disorders; Interleukin (IL) 1 ; TNFRSF1A gene; Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CANAKINUMAB; CASPASE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DEATH RECEPTOR; ETANERCEPT; FIBRINOGEN; HAPTOGLOBIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; X BOX BINDING PROTEIN 1;

AMYLOIDOSIS; APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; C1R GENE; C1S GENE; CD27 GENE; CD4 GENE; CELL PROLIFERATION; CHROMOSOME 12P; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DERMATITIS; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE TUBE; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ERYTHROCYTE SEDIMENTATION RATE; ETHNIC GROUP; EUROPEAN; EYE INFLAMMATION; FEVER; GENE; GENE INDUCTION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; LABORATORY DIAGNOSIS; LAG 3 GENE; MEDICAL LITERATURE; MUSCULOSKELETAL SYSTEM INFLAMMATION; NONHUMAN; ONSET AGE; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; QUALITY OF LIFE; RELAPSE; REVIEW; SEROSA; SIGNAL TRANSDUCTION; TNFRSF1A GENE; TRANSCRIPTION INITIATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UNFOLDED PROTEIN RESPONSE;

GENETIC PREDISPOSITION TO DISEASE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUTATION; PHENOTYPE; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RISK FACTORS;

EID: 84884993075     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. TOUITOU I, KONÉ-PAUT I: Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008; 22: 811-29.
2. CANTARINI L, RIGANTE D, BRIZI MG et al.: Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 2012; 44: 664-73.
3. McDERMOTT MF, AKSENTIJEVICH I, GALON J et al.: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
4. AGANNA E, HAMMOND L, HAWKINS PN et al.: Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48: 2632-44.
5. AKSENTIJEVICH I, GALON J, SOARES M et al.: The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotypephenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 301-14.
6. HULL KM, DREWE E, AKSENTIJEVICH I et al.: The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81: 349-68.
7. DODÉ C, ANDRÉ M, BIENVENU T et al. for the French Hereditary Recurrent Inflammatory Disorder Study Group: The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46: 2181-8.
8. CANTARINI L, LUCHERINI OM, BALDARI CT, LAGHI PASINI F, GALEAZZI M: Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 2010; 28: 405-7.
9. CANTARINI L, LUCHERINI OM, CIMAZ R, BALDARI CT, LAGHI PASINI F, GALEAZZI M: Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptorassociated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 2010; 28: 290-1.
10. CANTARINI L, LUCHERINI OM, BRUCATO A et al.: Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 2012; 101: 525-31.
11. CANTARINI L, LUCHERINI OM, CIMAZ R, GALEAZZI M: Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 2010; 28: 802.
12. Ter HAAR N, LACHMANN H, OZEN S et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO ) and the Eurofever/Eurotraps Projects: Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
13. CANTARINI L, LUCHERINI OM, IACOPONI F et al.: Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. Int J Immunopathol Pharmacol 2010; 23: 1133-41.
14. CANTARINI L, IACOPONI F, LUCHERINI OM et al.: Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. Int J Immunopathol Pharmacol 2011; 24: 695-702.
15. MUSCARI I, IACOPONI F, CANTARINI L et al.: The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev 2012; 12: 10-3.
16. CANTARINI L, LUCHERINI OM, MUSCARI I et al.: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012; 12: 38-43.
17. WILLIAMSON LM, HULL D, MEHTA R, REEVES WG, ROBINSON BH, TOGHILL PJ: Familial Hibernian fever. Q J Med 1982; 51: 469-80.
18. McDERMOTT MF, OGUNKOLADE BW, Mc- DERMOTT EM et al.: Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 998; 62: 1446-51.
19. NEDJAI B, HITMAN GA, YOUSAF N et al.: Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 273-83.
20. SARRAUSTE de MENTHIÈRE C, TERRIÈRE S, PUGNÈRE D et al. for INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003; 31: 282-5.
21. CHAN FK, CHUN HJ, ZHENG L, SIEGEL RM, BUI KL, LENARDO MJ: A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-4.
22. BANNER DW, D'ARCY A, JANES W et al.: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431-45.
23. REBELO SL, BAINBRIDGE SE, AMEL-KASHIPAZ MR et al.: Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptorassociated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006; 54: 2674-87.
24. RAVET N, ROUAGHE S, DODÉ C et al.: Clinical significance of P46L and R92Q substitutions in the tumor necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65: 1158-62.
25. TCHERNITCHKO D, CHIMINQGI M, GALACTÉROS F et al.: Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 2005; 13: 513-5.
26. BAZZONI F, BEUTLER B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25.
27. WAJANT H, PFIZENMAIER K, SCHEURICH P: Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
28. KIMBERLEY FC, LOBITO AA, SIEGEL RM, SCREATON GR: Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007; 9: 217.
29. NAISMITH JH, DEVINE TQ, BRANDHUBER BJ, SPRANG SR: Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 1995; 270: 13303-7.
30. BAUD V, KARIN M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 372-7.
31. PORTEU F, NATHAN C: Shedding of tumor necrosis factor receptors by activated human neutrophilis. J Exp Med 1990; 172: 599-607.
32. KALLINICH T, BRIESE S, ROESLER J et al.: Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004; 31: 2519-22.
33. STOJANOV S, DEJACO C, LOHSE P et al.: Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008; 67: 1292-8.
34. D'OSUALDO A, FERLITO F, PRIGIONE I et al.: Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54: 998-1008.
35. CHURCHMAN SM, CHURCH LD, SAVIC S et al.: A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF- kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2008; 67: 1589-95.
36. YOUSAF N, GOULD DJ, AGANNA E et al.: Tumor necrosis factor receptor I from patients with tumor necrosis factor receptorassociated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation. Arthritis Rheum 2005; 52: 2906- 16.
37. LOBITO AA, KIMBERLEY FC, MUPPIDI JR et al.: Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108: 1320-7.
38. SIEBERT S, FIELDING CA, WILLIAMS BD, BRENNAN P: Mutations of the extracellular domain of tumour necrosis factor receptor I causes reduced NF-κB activation due to decreased surface expression. FEBS Lett 2005; 579: 5193-8.
39. SIMON A, PARK H, MADDIPATI R et al.: Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci USA 2010; 107: 9801-6.
40. BULUA AC, SIMON A, MADDIPATI R et al.: Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519-33.
41. DICKIE LJ, AZIZ AM, SAVIC S et al.: Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2012; 71: 2035-43.
42. PAHL HL, BAEUERLE PA: The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 1997; 22: 63-7.
43. TODD I, RADFORD PM, DRAPER-MORGAN KA et al.: Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptorassociated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004; 113: 65-79.
44. LISBONA F, ROJAS-RIVERA D, THIELEN P et al.: BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha. Mol Cell 2009; 33: 679-91.
45. SAITOH T, FUJITA N, JANG MH et al.: Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456: 264-68.
46. NAKAHIRA K, HASPEL JA, RATHINAM VA et al.: Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222- 30.
47. BACCHETTI T, CHIESA S, CASTAGNOLA P et al.: Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 2013; 72: 1044-52.
48. TOUITOU I, LESAGE S, McDERMOTT M et al.: Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004; 24: 194-8.
49. CENTOLA M, AKSENTIJEVICH I, KASTNER DL: The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Hum Mol Genet 1998; 7: 1581-8.
50. CANTARINI L, LUCHERINI OM, CIMAZ R et al.: Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 2009; 22: 1051-8.
51. CANTARINI L, LUCHERINI OM, VITALE A et al.: Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis: report of two cases and review of the literature. Intern Med J 2013 (in press).
52. CANTARINI L, IMAZIO M, BRUCATO A, LUCHERINI OM, GALEAZZI M: Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 2010; 9: 436-40.
53. SCHMALTZ R, VOGT T, REICHRATH J: Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2010; 2: 26-9.
54. HULL KM, WONG K, WOOD GM, CHU WS, KASTNER DL: Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 2002; 46: 2189-94.
55. TROST S, ROSÉ CD: Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 2005; 32: 175-7.
56. RIGANTE D, CAPOLUONGO E: The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clin Chem Lab Med 2011; 49: 783-91.
57. OBICI L, MERLINI G: Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 2012; 12: 14-7.
58. CANTARINI L, LUCHERINI OM, CIMAZ R, GALEAZZI M: Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 2010; 28: 802.
59. CANTARINI L, RIGANTE D, LUCHERINI OM et al.: Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 2010; 23: 701-7.
60. CHIA S, QADAN M, NEWTON R, LUDLAM CA, FOX KA, NEWBY DE: Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003; 23: 695-701.
61. POIRIER O, NICAUD V, GARIÉPY J et al.: Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness--the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet 2004; 12: 213-9.
62. RIGANTE D, CANTARINI L, IMAZIO M et al.: Autoinflammatory diseases and cardiovascular manifestations. Ann Med 2011; 43: 341-6.
63. OBICI L, RAIMONDI S, LAVATELLI F, BELLOTTI V, MERLINI G: Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009 15; 61: 1435-40.
64. PIETZSCH J, HOPPMANN S: Human S100A12: a novel key player in inflammation? Amino Acids 2009; 36: 381-9.
65. CANTARINI L, OBICI L, SIMONINI G et al.: Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptorassociated periodic syndrome (TRAPS). Clin Exp Rheumatol 2012; 30 (Suppl. 72): S108- 14.
66. NOWLAN ML, DREWE E, BULSARA H et al.: Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 2006; 45: 31-7
67. DREWE E, McDERMOTT EM, POWELL PT, ISAACS JD, POWELL RJ: Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42: 235-9.
68. ARÓSTEGUI JI, SOLÍS P, ALDEA A et al.: Etanercept plus colchicine treatment in a child with tumour necrosis factor receptorassociated periodic syndrome abolishes autoinflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 2005; 164: 13-6.
69. KUSUHARA K, HOSHINA T, SAITO M et al.: Successful treatment of a patient with tumor necrosis factor receptor-associated periodic syndrome using a half-dose of etanercept. Pediatr Int 2012; 54: 552-5.
70. DREWE E, HUGGINS ML, MORGAN AG, CASSIDY MJ, POWELL RJ: Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004; 43: 1405-8.
71. DREWE E, McDERMOTT EM, POWELL RJ: Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000; 343: 1044-5.
72. BULUA AC, MOGUL DB, AKSENTIJEVICH I et al.: Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, doseescalation study. Arthritis Rheum 2012; 64: 908-13.
73. GATTORNO M, PELAGATTI MA, MEINI A et al.: Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
74. DREWE E, POWELL RJ, McDERMOTT EM: Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 2007; 46: 1865-6.
75. JACOBELLI S, ANDRE M, ALEXANDRA JF, DODE C, PAPO T: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 2007; 46: 1211-2.
76. CHURCH LD, CHURCHMAN SM, HAWKINS PN, McDERMOTT MF: Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 2006; 27: 494-508.
77. SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
78. NEDJAI B, HITMAN GA, QUILLINAN N et al.: Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009; 60: 619-25.
79. OBICI L, MEINI A, CATTALINI M et al.: Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011; 70: 1511-2.
80. QUILLIANAN N, MANNION G, MOHAMMAD A et al.: Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 2011; 70: 1692-3.
81. BRIZI MG, GALEAZZI M, LUCHERINI OM, CANTARINI L, CIMAZ R: Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 2012; 156: 907-8.
82. GATTORNO M, OBICI L, MEINI A et al.: Efficacy and safety of canakinumab patients with TNF Receptor-Associated Syndrome (TRAPS). Ann Rheum Dis 2012; 71 (Suppl. 3): 289.
83. VAITLA PM, RADFORD PM, TIGHE PJ et al.: Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63: 1151-5.